Use of antiarrhythmic drugs in elderly patients

Hon-Chi Lee1, Kristin Tl Huang, Win-Kuang Shen

  • 1Division of Cardiovascular Diseases, Department of Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA.

Insights

Aging significantly impacts cardiac electrophysiology and antiarrhythmic drug efficacy in older adults. Understanding these age-related changes is crucial for safe and effective arrhythmia management in the elderly.

Area of Science:

  • Cardiology
  • Gerontology
  • Pharmacology

Background:

  • Human aging is a global concern, increasing the incidence of health conditions and disability.
  • Cardiac arrhythmias, such as atrial fibrillation and sudden cardiac death, rise sharply after age 60.
  • Distinguishing physiological aging effects from pathological alterations in cardiac electrophysiology is vital.

Purpose of the Study:

  • To differentiate normal age-related cardiac electrophysiological changes from pathological alterations.
  • To examine how aging affects the pharmacokinetics and pharmacodynamics of antiarrhythmic drugs.
  • To highlight considerations for antiarrhythmic drug use in elderly patients.

Main Methods:

  • Review of age-related structural and electrophysiological changes in the heart.
  • Analysis of how aging impacts the absorption, distribution, metabolism, and elimination of antiarrhythmic medications.
  • Consideration of co-morbidities, polypharmacy, and drug-drug interactions in elderly patients.

Main Results:

  • Age-related cardiac changes include hypertrophy, amyloidosis, valvular degeneration, conduction system fibrosis, and pacemaker cell loss.
  • Electrophysiological changes involve altered ion channel expression and intracellular calcium overload, promoting arrhythmias.
  • Aging modifies antiarrhythmic drug pharmacokinetics/pharmacodynamics, necessitating monitoring of liver/kidney function and potential dose adjustments.

Conclusions:

  • Age-related cardiac alterations predispose individuals to arrhythmias.
  • Antiarrhythmic drug efficacy and safety are influenced by aging, increasing susceptibility to side effects.
  • Individualized antiarrhythmic therapy, considering patient physiology, comorbidities, and polypharmacy, is essential for the elderly.

Related Concept Videos

Drug Dosing: Geriatric Patients01:15

Drug Dosing: Geriatric Patients

Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Pharmacodynamics in Geriatric Patients: Effects of Age01:27

Pharmacodynamics in Geriatric Patients: Effects of Age

Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution01:00

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution

Drug distribution in the human body is influenced by several factors, including plasma protein concentration, body composition, blood flow, tissue-protein concentration, and tissue fluid pH. Among these, changes in plasma protein concentration and body composition due to aging significantly affect how drugs are distributed within the body. Specifically, aging is associated with a decrease in albumin levels by about 10% and an increase in α1-acid glycoprotein levels. These alterations are not...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion

In geriatric patients, renal physiology undergoes significant changes, including diminished renal blood flow and a lower glomerular filtration rate (GFR), leading to alterations in medication clearance. Drugs such as aminoglycoside antibiotics, lithium, and digoxin, which rely on glomerular filtration for removal from the body, particularly impact pharmacokinetics. These drugs tend to have slower clearance rates in older adults, necessitating careful dosage considerations.Evaluation of renal...